Precision BioSciences
Market Cap
US$429.9m
Last Updated
2020/07/08 23:58 UTC
Data Sources
Company Financials +
Executive Summary
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Precision BioSciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DTIL's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.2%
DTIL
2.0%
US Biotechs
2.3%
US Market
1 Year Return
-42.1%
DTIL
27.6%
US Biotechs
6.7%
US Market
Return vs Industry: DTIL underperformed the US Biotechs industry which returned 26.3% over the past year.
Return vs Market: DTIL underperformed the US Market which returned 6% over the past year.
Shareholder returns
| DTIL | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.2% | 2.0% | 2.3% |
| 30 Day | 1.0% | 7.4% | -0.7% |
| 90 Day | 31.6% | 25.3% | 17.1% |
| 1 Year | -42.1%-42.1% | 28.8%27.6% | 9.0%6.7% |
| 3 Year | n/a | 34.6%30.2% | 36.7%27.8% |
| 5 Year | n/a | -3.3%-8.8% | 65.2%46.9% |
Price Volatility Vs. Market
How volatile is Precision BioSciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Will Precision BioSciences (NASDAQ:DTIL) Spend Its Cash Wisely?2 months ago | Simply Wall St
The Precision BioSciences (NASDAQ:DTIL) Share Price Is Down 46% So Some Shareholders Are Getting Worried3 months ago | Simply Wall St
Precision BioSciences, Inc. Just Reported And Analysts Have Been Cutting Their EstimatesValuation
Is Precision BioSciences undervalued compared to its fair value and its price relative to the market?
3.71x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DTIL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DTIL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DTIL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: DTIL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DTIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DTIL is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Precision BioSciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
26.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DTIL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DTIL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DTIL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DTIL's revenue (50.7% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: DTIL's revenue (50.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DTIL is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Precision BioSciences performed over the past 5 years?
-49.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DTIL is currently unprofitable.
Growing Profit Margin: DTIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DTIL is unprofitable, and losses have increased over the past 5 years at a rate of -49.9% per year.
Accelerating Growth: Unable to compare DTIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DTIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: DTIL has a negative Return on Equity (-76.44%), as it is currently unprofitable.
Next Steps
Financial Health
How is Precision BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: DTIL's short term assets ($166.8M) exceed its short term liabilities ($23.8M).
Long Term Liabilities: DTIL's short term assets ($166.8M) exceed its long term liabilities ($75.4M).
Debt to Equity History and Analysis
Debt Level: DTIL is debt free.
Reducing Debt: DTIL had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DTIL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DTIL has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 70.6% each year.
Next Steps
Dividend
What is Precision BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DTIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DTIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DTIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DTIL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DTIL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average management tenure
CEO
Matt Kane (43yo)
14.5yrs
Tenure
US$2,166,460
Compensation
Mr. Matthew R. Kane, also known as Matt, co-founded Precision BioSciences, Inc. and has been its President, Chief Executive Officer and director since inception in 2006. Mr. Kane has a wealth of life sci ...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD2.17M) is about average for companies of similar size in the US market ($USD2.13M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.5yrs | US$2.17m | 3.52% $15.1m | |
| General Counsel & Secretary | 1.08yrs | US$1.71m | 0.0040% $17.2k | |
| Chief Medical Officer | 1.17yrs | US$2.18m | 0.0048% $20.6k | |
| Co-Founder & CTO | no data | no data | 7.41% $31.9m | |
| Chief Financial Officer | 1.42yrs | US$1.42m | 0.28% $1.2m | |
| Chief Operating Officer | 0.83yr | US$1.86m | 0.23% $970.9k | |
| Co-Founder | 14.5yrs | no data | 7.45% $32.0m | |
| Vice President of Financial Strategy & Investor Relations | 0.83yr | no data | no data | |
| Vice President of Quality & Compliance | 0.50yr | no data | no data | |
| Director of Marketing Communications & PR | no data | no data | no data |
1.1yrs
Average Tenure
43.5yo
Average Age
Experienced Management: DTIL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.5yrs | US$2.17m | 3.52% $15.1m | |
| Co-Founder | 14.5yrs | no data | 7.45% $32.0m | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 1.5yrs | US$326.28k | no data | |
| Independent Chairman | 0.33yr | US$361.96k | no data | |
| Independent Director | 1.58yrs | US$55.18k | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
1.6yrs
Average Tenure
60.5yo
Average Age
Experienced Board: DTIL's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
Top Shareholders
Company Information
Precision BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Precision BioSciences, Inc.
- Ticker: DTIL
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$429.931m
- Shares outstanding: 51.86m
- Website: https://www.precisionbiosciences.com
Number of Employees
Location
- Precision BioSciences, Inc.
- Dibrell Building
- Suite A-100
- Durham
- North Carolina
- 27701
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DTIL | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 2019 |
| PBS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 2019 |
Biography
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/08 23:58 |
| End of Day Share Price | 2020/07/08 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.